The UvA-LINKER will give you a range of other options to find the full text of a publication (including a direct link to the full-text if it is located on another database on the internet).
De UvA-LINKER biedt mogelijkheden om een publicatie elders te vinden (inclusief een directe link naar de publicatie online als deze beschikbaar is in een database op het internet).

Zoekresultaten

Zoekopdracht: journal id: "aids"

AuteursA.M. Kesselring, F.W. Wit, C.A. Sabin, J.D. Lundgren, M.J. Gill, J.M. Gatell, A. Rauch, J.S. Montaner, F. de Wolf, P. Reiss, A. Mocroft
TitelRisk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
TijdschriftAIDS
Jaargang23
Jaar2009
Nummer13
Pagina's1689-1699
ISSN02699370
FaculteitAMC-UvA
SamenvattingBackground: This collaboration of seven observational clinical cohorts investigated risk factors for treatment-limiting toxicities in both anti retroviral-naive and experienced patients starting nevirapine-based combination antiretroviral therapy (NVPc). Methods: Patients starting NVPc after 1 January 1998 were included. CD4 cell count at starting NVPc was classified as high (>400/mu l/>250/mu l for men/women, respectively) or low. Cox models were used to investigate risk factors for discontinuations due to hypersensitivity reactions (HSR, n = 6547) and discontinuation of NVPc due to treatment-limiting toxicities and/or patient/physician choice (TOXPC, n = 10 186). Patients were classified according to prior antiretroviral treatment experience and CD4 cell count/viral load at start NVPc. Models were stratified by cohort and adjusted for age, sex, nadir CD4 cell count, calendar year of starting NVPc and mode of transmission. Results: Median time from starting NVPc to TOXPC and HSR were 162 days [interquartile range (IQR) 31 -737] and 30 days (IQR 17-60), respectively. In adjusted Cox analyses, compared to naive patients with a low CD4 cell count, treatment-experienced patients with high CD4 cell count and viral load more than 400 had a significantly increased risk for HSR [hazard ratio 1.45, confidence interval (CI) 1.03-2.03] and TOXPC within 18 weeks (hazard ratio 1.34, Cl 1.08-1.67). In contrast, treatment-experienced patients with high CD4 cell count and viral load less than 400 had no increased risk for HSR 1.10 (0.82-1.46) or TOXPC within 18 weeks(hazard ratio 0.94, Cl 0.78-1.13). Conclusion: Our results suggest it may be relatively well tolerated to initiate NVPc in anti retroviral-experienced patients with high CD4 cell counts provided there is no detectable viremia. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
Soort documentArtikel
Document finderUvA-Linker